Skip to main content
Fig. 5 | Clinical Epigenetics

Fig. 5

From: Epigenetic inactivation of the extracellular matrix metallopeptidase ADAMTS19 gene and the metastatic spread in colorectal cancer

Fig. 5

ADAMTS19 hypermethylation and CRC tumor progression and invasion. a Incidence of ADAMTS19 hypermethylation in adenomas (ADE), primary CRCs (grouping Dukes’ A + B and C + D), and metastases (MET). b Incidence of ADAMTS19 hypermethylation in Dukes’ D primary cancers that metastasized to distant (mostly the liver or lung) or to local (mostly the ovary or omentum) organs and in metastases (MET). c Incidence of ADAMTS19 methylation vs CRC progression in primary cancers (Dukes’ scale, grouping A/B and C/D). d Incidence of ADAMTS19 methylation and depth of invasion in primary cancers (TNM scale, grouping T1/2 and T3/4). P values were calculated by Fisher’s exact test (b) and by Cochran-Armitage test for trends (a, c, and d)

Back to article page